Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.
By D. Bell, T. Lynch, Sara M. Haserlat, Patricia L. Harris, R. Okimoto, Brian W. Brannigan, D. Sgroi, Beth Muir, M. Riemenschneider, R. Iacona and 10 more. Journal of Clinical Oncology, 2005
623 citations recorded by the source corpus.
Subfields: Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/87afebfe1bf56181cb44789b322846d4a82f3e39
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap) (2013, background): “EGFRmutations are known to occur most frequently in ADC tumors and those of non smoking patients [11, 12].”
- EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). (2015, background): “Molecular profiling of tumor samples from patients with NSCLC has identified driver mutations that may contribute to early carcinogenesis in more than 80% of ADC cases, including epidermal growth factor receptor (EGFR) mutations [5], which are now considered to be commonly associated with NSCLC tumo”
- American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. (2009, background): “Twenty-four studies were retrospective, including five analyses of the major clinical trials involving gefitinib and erlotinib.(124,126,128,131,141) It is important to note that in these five analyses, tumor specimen collection was not mandated, and the percentage of patients’ tumors examined for bi”